Esophageal disease in scleroderma

J Clin Gastroenterol. 2006 Oct;40(9):769-75. doi: 10.1097/01.mcg.0000225549.19127.90.


Progressive systemic sclerosis (PSS) causes smooth muscle atrophy and fibrosis of the distal two-thirds of the esophagus. Motility studies show reduced-amplitude or absent peristaltic contractions in this region and normal or decreased lower esophageal sphincter pressure. Patients complain of dysphagia, heartburn, and regurgitation due to reflux and dysmotility. Complications include strictures found in 17% to 29% of patients and Barrett esophagus is 0% to 37%. Candida esophagitis is a complication of PSS not seen with non-PSS reflux. Esophageal disease correlates with pulmonary involvement but not with disease in the stomach or intestines. Whether reflux contributes to the pulmonary disease is an open question. Although manometry is the gold standard for diagnosis, cine-esophagram and scintography are only slightly less sensitive and should be considered for following the patients. Symptoms correlate poorly with evidence of esophagitis or abnormal 24-hour pH recordings. As a result, it is unclear which patients should receive acid-reducing or prokinetic medications and which medication to use. Aspiration precautions are important in those with severe esophageal dysmotility. This review of the literature highlights many areas of uncertainty in the diagnosis and treatment of esophageal disease in PSS that can be addressed in clinical studies.

Publication types

  • Review

MeSH terms

  • Autonomic Nervous System / physiopathology
  • Disease Progression
  • Esophageal Diseases / diagnosis
  • Esophageal Diseases / diagnostic imaging
  • Esophageal Diseases / etiology*
  • Esophagus / diagnostic imaging
  • Gastroesophageal Reflux / complications
  • Humans
  • Life Style
  • Lung Diseases / etiology
  • Lung Diseases / physiopathology
  • Manometry
  • Radionuclide Imaging
  • Scleroderma, Diffuse / complications*
  • Scleroderma, Diffuse / diagnosis